Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Revolution Medicines
Research
AACR: KRAS inhibitors pop in preclinical data debuts
Verastem Oncology, Quanta Therapeutics, Frontier Medicines and more showed off new preclinical data on drugs against the once-”undruggable” target.
Helen Floersh
Apr 11, 2024 4:30am
The unraveling of EQRx's low-cost drug dream
Oct 5, 2023 10:47am
EQRx's low cost drug dream ends in Revolution
Aug 1, 2023 8:49am
Sanofi sets Revolution back, sending lead asset to the docks
Dec 8, 2022 7:14am
Agios replaces CEO after recent FDA nod—Chutes & Ladders
Jul 15, 2022 9:30am
Amgen touts early combo data with Sanofi-backed KRAS partner
Jul 12, 2022 7:30pm
